Articles

Colorectal Cancer: Epidemiology, Risk Factors, and Public Health Strategies

Takahisa Matsuda, Ai Fujimoto, Yoshinori Igarashi . Digestion. 2025;106(2):91-99

Colorectal cancer (CRC) is a significant global health issue, ranking as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths. Countries with a high Human Development Index (HDI) report the highest incidence rates, driven by dietary and lifestyle factors. In contrast, low-to-mi... Read More

24 Mar, 2026

European cancer mortality predictions for the year 2024 with focus on colorectal cancer

C. Santucci, S. Mignozzi, M. Malvezzi, et al. Ann Oncol. 2024 Mar;35(3):308-316

We predicted cancer mortality figures for 2024 for the European Union (EU), its five most populous countries, and the UK. We predicted cancer mortality figures for 2024 for the European Union (EU), its five most populous countries, and the UK. We predicted 1 270 800 cancer deaths for 2024 in the EU, corresponding to AS... Read More

24 Mar, 2026

Evolving landscape of colorectal cancer: Global and regional burden, risk factor dynamics, and future scenarios (the Global Burden of Disease 1990-2050)

Jiajie Zhou, Qizhi Yang, Shuai Zhao,et al. Ageing Res Rev. 2025 Feb:104:102666

Presently, colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. We provided global, regional, and national estimates of the burden of CRC and their attributable risks from 1990 to 2021, aiming to guide screening, early detection, and treatment strategies, optimize healthcare resource ... Read More

24 Mar, 2026

Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: The urgent need to address inequalities in cervical cancer

Zhuang Li, Penglin Liu, Aijun Yin,et al. Int. J. Cancer. 2025;157:288–297

Cervical cancer remains a major public health challenge worldwide, despite being largely preventable through effective interventions. Timely evidence regarding the global landscape of cervical cancer is crucial for measuring the magnitude of inequalities and monitoring progress towards cervical cancer elimination. We a... Read More

24 Mar, 2026

Global trends and future projections of cervical cancer burden: an integrated analysis of GBD 2021, UN population and WHO HPV vaccination data

Dongxuan Shao, Ping Wu, Huici Jiang , et al. Front Public Health 2026 Jan 26:14:1702186

Cervical cancer remains a leading cause of morbidity and mortality among women, disproportionately affecting low- and middle-income countries (LMICs). We sought to: (1) characterize temporal and geographic patterns of cervical cancer burden (1990-2021), with a focus on age-related differences; (2) identify attributable... Read More

24 Mar, 2026

Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial

Henry M Kuerer 1, Vicente Valero 2, Benjamin D Smith 3, et al. JAMA Oncol. 2025 May 1;11(5):529-534

Neoadjuvant systemic therapy (NST) has been associated with pathologic complete response (pCR) in up to 60% of breast cancers (BCs). The findings of this trial question the necessity of surgery. To report preplanned 5-year efficacy outcomes evaluating radiotherapy alone without breast surgery in patients selected with ... Read More

24 Mar, 2026

Society of Surgical Oncology Breast Disease Site Working Group Statement on Bilateral Risk-Reducing Mastectomy: Indications, Outcomes, and Risks

Puneet Singh, Doreen M Agnese, Miral Amin, et al. Ann Surg Oncol. 2025 Feb;32(2):899-911.

Bilateral risk-reducing mastectomy (BRRM) is the surgical removal of both breasts to reduce the risk of cancer. In this Society of Surgical Oncology position statement, we review the literature addressing the indications, outcomes, and risks of BRRM to update the society's 2017 statement. We held a virtual meeting to o... Read More

24 Mar, 2026

Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study

Eva Blondeaux 1, Amir Sonnenblick 2, Elisa Agostinetto . Lancet Oncol. 2025 Jun;26(6):759-770

The BRCA BCY Collaboration is an international, hospital-based, retrospective cohort study, conducted at 109 centers in five continents, including women harboring germline BRCA1, BRCA2, or both, pathogenic or likely pathogenic variants and diagnosed with stage I–III invasive breast cancer at the age of 40 years or youn... Read More

24 Mar, 2026

Defining Lifetime Risk Thresholds for Breast Cancer Surgical Prevention

Xia Wei , Lea Mansour , Samuel Oxley, et al. JAMA Oncol. 2025 Jul 24;11(9):1072-1082.

Expanding access to genetic testing and availability of validated breast cancer (BC) risk prediction models are increasingly identifying women at elevated BC risk who do not carry high-penetrance BRCA1/BRCA2/PALB2 pathogenic variants.  In the simulated cohort of 100 000 thirty-year-old women in the UK, undergoing RRM b... Read More

24 Mar, 2026

Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status

Matteo Lambertini , Eva Blondeaux , Loredana M Tomasello.et al. J Clin Oncol. 2025 May 10;43(14):1706-1719

To investigate the clinical behavior of breast cancer in young BRCA carriers according to the specific BRCA gene (BRCA1 v BRCA2) and the association of the timing of genetic testing (before v at diagnosis) with prognosis. Compared with BRCA2 carriers (n = 1,683), BRCA1 carriers (n = 3,069) had more frequently hormone r... Read More

24 Mar, 2026